Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients

Noordam, Lisanne; Beijer, Monique T A de; Mancham, Shanta; Vogler, Isabel; Boor, Patrick P.C.; Ruiter, Valeska de; Luijten, Robbie; IJzermans, Jan N.M.; Şahin, Uğur; Bruno, Marco J.; Sprengers, Dave; Buschow, Sonja I.; Kwekkeboom, Jaap

doi:10.1080/2162402x.2022.2131096

Cited by 2 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…i.e., toll-like receptor (TLR) agonists, vaccination, radiation or low dose metronomic chemotherapy to achieve immunogenic cell death. In HCC, previous locoregional therapies demonstrate to enhance Ki67 expression in HCC-derived TILs ( 126 , 224 ). Thus, these data support the concept of priming the TIME prior to ICS-mediated anti-tumour immunity in PLC.…”

Section: Enhancing Ics-mediated Anti-tumour Activity In Plcmentioning

confidence: 99%

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Rakké,

Buschow,

IJzermans

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the first and second most common primary liver cancer (PLC). For decades, systemic therapies consisting of tyrosine kinase inhibitors (TKIs) or chemotherapy have formed the cornerstone of treating advanced-stage HCC and CCA, respectively. More recently, immunotherapy using immune checkpoint inhibition (ICI) has shown anti-tumour reactivity in some patients. The combination regimen of anti-PD-L1 and anti-VEGF antibodies has been approved as new first-line treatment of advanced-stage HCC. Furthermore, gemcibatine plus cisplatin (GEMCIS) with an anti-PD-L1 antibody is awaiting global approval for the treatment of advanced-stage CCA. As effective anti-tumour reactivity using ICI is achieved in a minor subset of both HCC and CCA patients only, alternative immune strategies to sensitise the tumour microenvironment of PLC are waited for. Here we discuss immune checkpoint stimulation (ICS) as additional tool to enhance anti-tumour reactivity. Up-to-date information on the clinical application of ICS in onco-immunology is provided. This review provides a rationale of the application of next-generation ICS either alone or in combination regimen to potentially enhance anti-tumour reactivity in PLC patients.

show abstract

Section: Enhancing Ics-mediated Anti-tumour Activity In Plcmentioning

confidence: 99%

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Rakké,

Buschow,

IJzermans

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

Progress in ubiquitination and hepatocellular carcinoma: A bibliometric analysis

Li,

Xu,

Liang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and Purpose Ubiquitination modifications can affect hepatocellular carcinoma (HCC) progression through various signaling pathways. However, no significant results have been observed regarding protein ubiquitination in HCC’s therapeutic transformation. This study aimed to explore the research areas related to ubiquitination and HCC from a bibliometric perspective.Methods Articles and reviews on HCC and ubiquitination published between 2000 and 2023 were obtained from the Web of Science Core Collection (WOSCC). CiteSpace, VOSviewer, and R-bibliometrix were used for the bibliometric and visualization analyses.Results Altogether, 358 papers on ubiquitination and HCC were extracted from the WOSCC. Over 24 years, the number of publications has increased. Since the beginning of 2019, studies related to this topic have increased significantly, indicating that the role of ubiquitination modification in HCC is currently popular. China is the leading country in this field with the largest number of publications. The Chinese Academy of Sciences is one of the most influential institutions. Qiao, Yongxia, and Zhang Jie are highly productive authors with major achievements. The journal Cell Death & Disease had the highest number of publications, and the most highly cited journal was Oncogene. The highest citation burst intensity was Sung (2021). In the keyword strategy map, “cancer antigens” are popular keywords in HCC and ubiquitination research.Conclusion A comprehensive visual analysis of ubiquitination and HCC research was conducted using bibliometric methods, showing the publications and popular topics in this field over the past two decades, thus providing references for the future direction of ubiquitination and HCC research.

show abstract

Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients

Cited by 2 publications

References 66 publications

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake

Progress in ubiquitination and hepatocellular carcinoma: A bibliometric analysis

Contact Info

Product

Resources

About